{"id":12675,"date":"2024-01-17T10:10:32","date_gmt":"2024-01-17T09:10:32","guid":{"rendered":"https:\/\/www.tauli.cat\/institut\/?p=12675"},"modified":"2024-01-22T16:25:47","modified_gmt":"2024-01-22T15:25:47","slug":"li3pt-guanya-2-beques-del-ministeri-per-un-valor-de-073-milions-deuros","status":"publish","type":"post","link":"https:\/\/www.tauli.cat\/institut\/actualitat\/noticies\/2024\/01\/li3pt-guanya-2-beques-del-ministeri-per-un-valor-de-073-milions-deuros\/","title":{"rendered":"L\u2019I3PT guanya 2 beques del Ministeri per un valor de m\u00e9s de 700.000 euros","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
[vc_row][vc_column][vc_column_text]L\u2019Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT) ha obtingut finan\u00e7ament per desenvolupar dos projectes\u00a0<\/strong>presentats a la convocat\u00f2ria competitiva \u201cProyectos de colaboraci\u00f3n p\u00fablico privada\u201d<\/strong>\u00a0de l\u2019Ag\u00e8ncia Estatal d\u2019Investigaci\u00f3 del\u00a0Ministeri de Ci\u00e8ncia i Innovaci\u00f3\u00a0<\/strong>per un valor de\u00a0733.241 euros<\/strong>.<\/p>\n

La concessi\u00f3 d’aquesta dotaci\u00f3, tal com ha subratllat la responsable de la Unitat de Projectes de l\u2019entitat, Anna Aguilar<\/strong>, \u201cservir\u00e0 per seguir investigant ter\u00e0pies que millorin la qualitat de vida de pacients amb malalties rares. Ambd\u00f3s projectes aborden necessitats espec\u00edfiques de condicions que sovint compten amb poca visibilitat i recursos per a la seva recerca\u201d.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/i><\/div>

Descobriment i desenvolupament cl\u00ednic de nous inhibidors de la PDE-10 per al tractament de la s\u00edndrome de Prader-Willi (PRAWILLI)<\/h3> <\/div><\/div>[vc_column_text]Investigadora principal: Assumpta Caix\u00e0s | 542.566 \u20ac<\/strong><\/p>\n

Objectiu<\/strong>: Avan\u00e7ar en el desenvolupament cl\u00ednic de PBF-999 per al tractament de la S\u00edndrome de Prader-Willi (SPW). Es desenvolupar\u00e0 un assaig cl\u00ednic de fase II per avaluar la seguretat, tolerabilitat i efic\u00e0cia d\u2019aquest component en la SPW. A m\u00e9s, en aquest projecte es dissenyaran i sintetitzaran nous compostos de reserva, i s\u2019avaluaran les seves propietats farmacol\u00f2giques en diferent proves in vitro i in vivo, i se seleccionaran les que siguin \u00f2ptimes. Es dur\u00e0 a terme una intensa activitat de Propietat Industrial per tal de protegir els nous compostos i els m\u00e8todes derivats dels biomarcadors trobats.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/i><\/div>

Assaig cl\u00ednic de Fase II d\u2019una ter\u00e0pia innovadora per a pacients amb S\u00edndrome X Fr\u00e0gil<\/h3> <\/div><\/div>[vc_column_text]Investigadora principal: Ana Roche | 190.675 \u20ac<\/strong><\/p>\n

Objectiu<\/strong>: Desenvolupar una nova ter\u00e0pia disruptiva per la s\u00edndrome X Fr\u00e0gil (SXF). La SXF \u00e9s un trastorn cognitiu-conductual d\u2019origen gen\u00e8tic causat per una defici\u00e8ncia a la prote\u00efna FMRP (Fragile X Messenger Ribonucleoprotein 1). L’objectiu principal de la proposta \u00e9s investigar CTH120 com una ter\u00e0pia efectiva per al tractament de l’SXF en pacients adults mitjan\u00e7ant un assaig cl\u00ednic de Fase IIa, a trav\u00e9s d’una col\u00b7laboraci\u00f3 interdisciplin\u00e0ria publico-privada entre l’empresa i entitats de recerca gen\u00f2mica i cl\u00ednica.[\/vc_column_text][\/vc_column][\/vc_row]\n<\/div>","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"

La dotaci\u00f3 servir\u00e0 per finan\u00e7ar l’assaig cl\u00ednic d\u2019una ter\u00e0pia innovadora per a pacients amb S\u00edndrome X Fr\u00e0gil i el descobriment i desenvolupament cl\u00ednic de nous inhibidors de la PDE-10 per al tractament de la s\u00edndrome de Prader-Willi<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":28,"featured_media":12684,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[235,58,296,56,180,295],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/posts\/12675"}],"collection":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/comments?post=12675"}],"version-history":[{"count":9,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/posts\/12675\/revisions"}],"predecessor-version":[{"id":12739,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/posts\/12675\/revisions\/12739"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/media\/12684"}],"wp:attachment":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/media?parent=12675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/categories?post=12675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/tags?post=12675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}